{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '1.', 'SYNOPSIS', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Short Title: Danirixin Pilot Study for Disease Progression in COPD', 'Rationale: This is a pilot study to investigate the effect of danirixin hydrobromide (HBr)', '35mg tablets on lung function and health related quality of life (HRQoL) in participants', 'with mild to moderate airflow obstruction and a demonstrated history of decline in FEV1.', 'This study aims to assess whether danirixin has the potential to impact disease', 'progression in participants with COPD and with a demonstrated history of disease', 'progression measured by lung function.', 'Objectives and Endpoints:', 'Objective', 'Endpoint', 'Primary', 'Rate of decline in FEV1', 'To assess whether danirixin HBr 35mg', 'tablets impact disease progression', \"Change from baseline in St. George's\", 'compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events', 'danirixin HBr 35mg tablets compared', 'Vital Signs', 'with placebo in participants with mild', 'ECG', 'to moderate airflow limitation', 'Clinical Laboratory Assessments', '(hematology, clinical chemistry,', 'urinalysis)', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared with placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Overall Design:', 'This is a Phase 2 study to investigate the potential impact of danirixin HBr 35mg tablets', 'compared with placebo on disease progression in participants with mild to moderate', '8']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'airflow obstruction. The study will also assess the enrichment strategy of enrolling', 'participants identified from the COPDGene study. These participants have been', 'identified by COPDGene investigators based on data collected over the initial 5 year', 'period. The participants were identified based on a Random Forest analysis and a', 'demonstrated decline of at least 20mL/yr over the initial 5 year period.', 'Number of Participants:', 'Approximately 130 participants will be screened to enrol 100 participants in this study. It', 'is anticipated that approximately 85 participants will complete the 52 weeks of treatment', '(assuming a 15% drop out rate).', 'Treatment Groups and Duration:', 'Participants will receive either placebo or danirixin 35mg tablets (as hydrobromide', 'hemihydrate salt) twice daily for 52 weeks (12months).', '9']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'Table 1', 'Schedule of activities', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'days', 'Visit1a', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Eligibility', 'Informed Consent', 'X', 'Genetics Informed Consentb', 'X', 'Demography', 'X', 'Inclusion and Exclusion Criteria', 'X', 'Smoking Statusc', 'X', 'Smoking Historyc', 'X', 'Medical Historyd', 'X', 'Full physical', 'Chest X-ray (historical within 1 year', 'acceptable)', 'HIV, Hepatitis B and C screeninge', 'Additional Eligibility and In Study Assessments', 'Verify Eligibility', 'X', 'Brief physical', 'X', 'Laboratory assessments (clinical chemistry,', 'including liver chemistries), hematology,', 'X', 'X', 'X', 'urinalysis', 'Additional Liver chemistries only', 'X', 'X', 'X', 'X', '12 lead ECG', 'X', 'X', 'X', 'Vital Signs', 'X', 'X', '10']\n\n###\n\n", "completion": "END"}